Transaction #27919 · Form 4 · 0001171843-26-000054
Compass Therapeutics, Inc. · Stock award · Stock Option (Right to Buy)
Compass Therapeutics, Inc. · Transacted January 2, 2026 · Filed January 5, 2026
What does this filing report?
An SEC Form 4 filing for Compass Therapeutics, Inc. records a stock award involving Stock Option (Right to Buy) on January 2, 2026. The reported quantity was 90,000. The filing date is January 5, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Compass Therapeutics, Inc.
- Company CIK
- 0001738021
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 90,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 90,000
- Ownership description
- Not reported
- SEC acceptance time
- Jan 5, 2026, 4:32 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Boylan James P ↗
Director
CIK 0001953094
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 90,000
- Conversion / exercise price
- 5.17
- Exercise date
- Not reported
- Expiration date
- January 2, 2036
Filing footnotes & remarks
- F1
- This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders.
- F2
- The Reporting Person is a member of Enavate Sciences, LP ("Enavate"). Pursuant to an agreement with Enavate, the Reporting Person is obligated to transfer any securities issued under any stock options or other awards, or the economic benefit thereof, to Enavate, which will in turn ensure that such securities or economic benefits are provided to Enavate
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.